Company profile
SUMMIT THERAPEUTICS INC.
NASDAQ:SMMTBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IVONESCIMAB | phase3 | — | 3 | active |
| RIDINILAZOLE | phase3 | — | 4 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02056808 | phase1 | completed | 2013-11-01 | 2014-05-01 | Summit Therapeutics | A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD) |
| NCT07815665 | phase2_3 | recruiting | 2026-09-10 | 2030-10-31 | Summit Therapeutics | A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma |
| NCT02784002 | phase2 | completed | 2014-12-01 | 2016-08-01 | Summit Therapeutics | A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI) |
| NCT02092935 | phase2 | completed | 2014-04-01 | 2015-10-01 | Summit Therapeutics | A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD) |
| NCT05899608 | phase3 | active_not_recruiting | 2023-10-26 | 2028-12-31 | Summit Therapeutics | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients |
FDA applications (0)
No records yet.